Harrow Health backs 2024 revenue guidance of at least $180M, consensus $184.91M

In a letter to stockholders disclosed by Harrow Health in a regulatory filing, the company stated: “Our revenue guidance for 2024 of at least $180 million remains intact. However, as more of our revenues come from branded products, we will be subject to more traditional pharma ‘revenue seasonality’ as co-pays and other patient co-insurance premiums are met during the course of the year. This means we expect the quarterly revenues to be stronger during the second half of 2024 than during the first half of 2024. Given these new key sources of revenue as well as the temporary disruption resulting from the Change cybersecurity incident, Harrow stockholders should expect quarterly revenue fluctuations; however, at this time next year, when we look back at the entirety of the calendar year, we believe our guidance will have been met.”